View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 17, 2019updated 12 Jul 2022 12:28pm

Optimal JIT, CTCA to speed-up patient enrolment in cancer trials

Global contract research organisation PPD’s Accelerated Enrollment Solutions (AES) business unit Optimal just-in-time (JIT) has entered into a partnership with Cancer Treatment Centers of America (CTCA).

Global contract research organisation PPD’s Accelerated Enrollment Solutions (AES) business unit Optimal just-in-time (JIT) has entered into a partnership with Cancer Treatment Centers of America (CTCA).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The collaboration aims to accelerate patient enrolment in oncology clinical trials and improve patient’s access to life-changing treatments.

It will also help save time for drug researchers in their pursuit to defeat cancer.

CTCA is a cancer care network of hospitals and outpatient care centres in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.

Integrating the CTCA managed sites with Optimal JIT approach has enabled cancer patients to enter trials faster and allowed AES clients to reduce the time needed for starting the trial.

The approach was successful in reducing site activation time from a maximum of eight months to a minimum of two weeks.

Data generated by CTCA shows results that exceed traditional sites on the same trials when analysing data currency, query rates, and retention.

PPD Optimal service offerings chief operating officer Krystyna Kowalczyk said: “Our collaboration with CTCA demonstrates how we are changing the paradigm of cancer care.

“Together, we are creating meaningful opportunities for cancer patients to participate in clinical trials and access innovative therapies close to home, allowing them to receive care within the context of their support networks in their own communities.

“Some 30% of the patients we enrol with CTCA are from under-represented populations, which reflect our goal of expanding clinical trial opportunities more broadly. Our goal is to enrol more patients from fewer sites in less time to support important oncology trials.

“Thanks to our JIT methodology, a two-week turnaround for first-patient-in is now possible.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena